Latest Non Dilutive Funding News

Tusker Minerals has completed the sale of its Malawi exploration subsidiary to AuKing Mining, receiving $800,000 in cash and 40 million escrowed AuKing shares. The deal gives Tusker further deferred and performance-linked consideration while redirecting its immediate funding capacity towards Cameroon and the retained Mzimba project.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Litchfield Minerals has expanded its Harts Range exploration model, raised A$8 million and ended FY2026 with A$4.6 million in cash. The opportunity is growing, but the auditor flagged material uncertainty over the company’s ability to fund future operations.

Titomic has set 30 November 2026 as its current target to complete a proposed move of its parent company from Australia to the United States. The ASX listing would remain, but investors would hold CHESS Depositary Interests in the new US entity if shareholders, the Court and other conditions approve the scheme.

Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Marquee Resources has received a $549,122 R&D tax refund, adding non-dilutive cash ahead of planned drilling at its Yindi Lithium and Gold Project in Western Australia. The filing improves near-term financial flexibility but does not disclose the company’s post-refund cash balance or drilling budget.

Ceretas has completed the third milestone of its government-backed CUREator+ program, unlocking a final $692,578 non-dilutive funding tranche. The work delivered functional prototypes of proprietary neuronavigation software and a lift assist device intended to simplify operation of its next-generation Alzheimer’s ultrasound system.

EMVision has completed the first stage of a Melbourne Mobile Stroke Unit study, operating its portable brain scanner in homes, ambulances and a workplace. The small, non-diagnostic feasibility study produced strong usability results while pointing to a larger clinical validation step planned for next-generation units.

Raptor Metals has sold its remaining Australian Gold and Copper stake for approximately $468,200, converting a legacy asset into cash without issuing new shares. The proceeds add funding flexibility as the company advances copper exploration in New Brunswick.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

NoviqTech has secured a one-year extension on its $1.4 million unsecured loan facility, maintaining favourable terms to support its push for ASX reinstatement.